E-viri
PDF
Recenzirano
Odprti dostop
-
Bielekova, Bibiana; Richert, Nancy; Howard, Thomas; Blevins, Gregg; Markovic-Plese, Silva; McCartin, Jennifer; Würfel, Jens; Ohayon, Joan; Waldmann, Thomas A.; McFarland, Henry F.; Martin, Roland
Proceedings of the National Academy of Sciences - PNAS, 06/2004, Letnik: 101, Številka: 23Journal Article
Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-β therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.
